Annals of Oncology 2014-Apr
Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
Chỉ người dùng đã đăng ký mới có thể dịch các bài báo
Đăng nhập Đăng ký
Liên kết được lưu vào khay nhớ tạm
Từ khóa
trừu tượng
BACKGROUND
This report examines 99mTc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide).PATIENTS AND METHODS
In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with 99mTc-etarfolatide before vintafolide treatment. Up to 10 target lesions (TLs) were selected based on Response Evaluation Criteria In Solid Tumors criteria using computed tomography scans. Single-photon emission computed tomography images of TLs were assessed for 99mTc-etarfolatide uptake as either FR positive or negative. Patients were categorized by percentage of TLs positive and grouped as FR(100%), FR(10%-90%), and FR(0%). Lesion and patient response were correlated with etarfolatide uptake.RESULTS
Forty-nine patients were enrolled; 43 were available for analysis. One hundred thirty-nine lesions were 99mTc-etarfolatide evaluable: 110 FR positive and 29 FR negative. Lesion disease control rate (DCR = stable or response) was observed in 56.4% of FR-positive lesions versus 20.7% of FR-negative lesions (P < 0.001). Patient DCR was 57%, 36%, and 33% in FR(100%), FR(10%-90%), and FR(0%) patients, respectively. Median overall survival was 14.6, 9.6, and 3.0 months in FR(100%), FR(10%-90%), and FR(0%) patients, respectively.CONCLUSIONS
Overall response to FR-targeted therapy and DCR correlate with FR positivity demonstrated by 99mTc-etarfolatide imaging.